Research Articles

Explore upcoming scientific meetings and educational events focused on advancing collaboration, sharing new evidence, and strengthening best practices in the care of patients with cancer-related cardiovascular conditions.

Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.

Authors:

Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J.

Publication:

Current Treatment Options Cardiovascular Medicine

Date:

2014 Sep

Article Link

Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities.

Authors:

Vejpongsa P, Yeh ET.

Publication:

Journal of the American College of Cardiology

Date:

2014 Sep 2

Article Link

Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study.

Authors:

Lorusso V, Giotta F, Bordonaro R, Maiello E, Del Prete S, Gebbia V, Filippelli G, Pisconti S, Cinieri S, Romito S, Riccardi F, Forcignanò R, Ciccarese M, Petrucelli L, Saracino V, Lupo LI, Gambino A, Leo S.

Publication:

International Journal of Oncology

Date:

2014 Nov

Article Link

Pharmacokinetics, Antitumor and Cardioprotective Effects of Liposome-Encapsulated Phenylaminoethyl Selenide in Human Prostate Cancer Rodent Models.

Authors:

Kang JY, Eggert M, Mouli S, Aljuffali I, Fu X, Nie B, Sheil A, Waddey K, Oldham CD, May SW, Amin R, Arnold RD.

Publication:

Pharmaceutical Research

Date:

2014 Aug 27

Article Link

Ottawa Cardiac Oncology Program wins 2013 Cancer Quality Council of Ontario Innovation Award.

Authors:

Sulpher J, Johnson C, Turek M, Law A, Stadnick E, Hopkins S, Graham N, Dent SF.

Publication:

Current Oncology

Date:

2014 Jun

Article Link

Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice.

Authors:

Hassan MH, El-Beshbishy HA, Aly H, Attia SM, Bahashwan SA, Ghobara MM.

Publication:

Cancer Chemotherapy and Pharmacology

Date:

2014 Sep

Article Link

Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of Doxorubicin cardiotoxicity.

Authors:

Khiati S, Dalla Rosa I, Sourbier C, Ma X, Rao VA, Neckers LM, Zhang H, Pommier Y.

Publication:

Clinical Cancer Research

Date:

2014 Sep 15

Article Link

Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: A review of the protective role of melatonin.

Authors:

Govender J, Loos B, Marais E, Engelbrecht AM.

Publication:

Journal of Pineal Res

Date:

2014 Sep 17

Article Link

Metformin Protects Cardiomyocyte from Doxorubicin Induced Cytotoxicity through an AMP-Activated Protein Kinase Dependent Signaling Pathway: An In Vitro Study.

Authors:

Kobashigawa LC, Xu YC, Padbury JF, Tseng YT, Yano N.

Publication:

PLoS One

Date:

2014 Aug 15

Article Link

Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.

Authors:

Lipshultz SE, Diamond MB, Franco VI, Aggarwal S, Leger K, Santos MV, Sallan SE, Chow EJ.

Publication:

Paediatric Drugs

Date:

2014 Oct

Article Link